Physician profile
Monifa Brooks
NPI 1386633105
$1,028.50
in general payments reported to CMS, 2019-2025
25 companies · $149 in 2025
The $149 reported for 2025 was more than what a typical Physical Medicine & Rehabilitation provider received nationally (typical 2025 total: $138).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $343 · 2020: $53.64 · 2021: $29.77 · 2022: $43.14 · 2023: $117 · 2024: $294 · 2025: $149.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $559.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $559.39 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $172.49 | 2022-2025 | Botox |
| Merz Pharmaceuticals, LLC | $137.60 | 2023-2025 | Xeomin, Inbrija |
| Azurity Pharmaceuticals, INC. | $80.77 | 2023-2025 | Horizant, Horizant |
| Allergan, INC. | $74.58 | 2019-2022 | |
| Merz North America, INC. | $56.75 | 2019 | |
| Avanir Pharmaceuticals, INC. | $56.24 | 2019-2020 | |
| Argenx US, INC. | $53.79 | 2024 | Vyvgart Hytrulo |
| Collegium Pharmaceutical, INC. | $39.62 | 2019-2020 | |
| Coloplast Corp | $37.63 | 2019-2024 | |
| Pfizer INC. | $29.75 | 2019 | |
| Vertex Pharmaceuticals Incorporated | $29.48 | 2024-2025 | |
| Bioventus LLC | $29.19 | 2024 | L300 Go System |
| Alexion Pharmaceuticals, INC. | $27.32 | 2020-2024 | Ultomiris |
| Pacira Therapeutics, INC. | $27.00 | 2019 | |
| Janssen Pharmaceuticals, INC | $25.07 | 2019 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $20.36 | 2019 | |
| Axsome Therapeutics, INC. | $17.95 | 2023 | Sunosi |
| Otsuka America Pharmaceutical, INC. | $16.27 | 2023 | Nuedexta |
| Lundbeck LLC | $15.52 | 2024 | Vyepti |
| Ultragenyx Pharmaceutical INC. | $14.14 | 2019 | |
| Biogen, INC. | $14.05 | 2019 | |
| Tersera Therapeutics LLC | $14.04 | 2019 | |
| Sanofi-Aventis U.S. LLC | $13.27 | 2020 | |
| Scilex Pharmaceuticals INC. | $13.17 | 2019 | |
| Biodelivery Sciences International, INC. | $12.45 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Monifa Brooks listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.